Adial PharmaceuticalsADIL
13F holders, Q1 2025 (March 31)12holders −1
2new positions
3sold out
$0.64avg. 13F price*
At the end of Q1 2025, 12 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, down 1 from Q4 2024. 2 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($44K), Manchester Capital Management LLC ($31K) and UBS Group AG ($30K).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A205
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $25K |
| Exits | 3 | $130K |
All 13F filers, Q4 2024 → Q1 2025: 74,095 shares bought and 129,131 shares sold, net −55,036 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Geode Capital Management, LLC | 0.00% | Add +11.3% | 68,850 | $44K |
| Manchester Capital Management LLC | 0.00% | No change | 48,097 | $31K |
| UBS Group AG | 0.00% | Add +127.2% | 47,745 | $30K |
| BlackRock, Inc. | 0.00% | No change | 27,770 | $18K |
| Virtu Financial LLC | 0.00% | New | 26,414 | $17K |
| Vanguard Group Inc. | 0.00% | New | 13,159 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +123.7% | 1,427 | $905 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -1.1% | 927 | $588 |
| Wells Fargo & Company | 0.00% | No change | 160 | $101 |
| Bank of America Corp. | 0.00% | Add +5.8% | 55 | $35 |
| Abound Wealth Management | 0.00% | No change | 27 | $18 |
| Morgan Stanley | 0.00% | No change | 9 | $6 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.